Answer
Yes, interstitial lung disease including pneumonitis, sometimes fatal, has occurred without an identified infectious cause in patients receiving sirolimus-containing immunosuppressive regimens; some cases resolved after discontinuation or dose reduction, and risk may increase with higher trough sirolimus levels.
Sources for this answer
- Rapamune 2 mg coated tabletsPfizer Limited · emc · SmPC §4.8 Undesirable effects · Version 54Document updated
Sources checked